140 related articles for article (PubMed ID: 32828115)
1. A pilot study into bosentan (Tracleer®) as an immunomodulating agent in patients with Behçet's disease.
Houwen TBV; Hagen PMV; Kappen JH; Kuijpers RWAM; Daele PLAV; Dik WAV; Laar JAMV
Asian Pac J Allergy Immunol; 2022 Dec; 40(4):435-441. PubMed ID: 32828115
[TBL] [Abstract][Full Text] [Related]
2. Saliva and Serum Cytokine Profiles During Oral Ulceration in Behçet's Disease.
Novak T; Hamedi M; Bergmeier LA; Fortune F; Hagi-Pavli E
Front Immunol; 2021; 12():724900. PubMed ID: 35003055
[TBL] [Abstract][Full Text] [Related]
3. [Behçet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients].
Stübiger N; Kötter I; Deuter C; Zierhut M
Klin Monbl Augenheilkd; 2001 Dec; 218(12):768-73. PubMed ID: 11805868
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study.
Matsuda T; Ohno S; Hirohata S; Miyanaga Y; Ujihara H; Inaba G; Nakamura S; Tanaka S; Kogure M; Mizushima Y
Drugs R D; 2003; 4(1):19-28. PubMed ID: 12568631
[TBL] [Abstract][Full Text] [Related]
5. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
6. High-dose intravenous steroid pulse therapy in ocular involvement of Behcet's disease: a pilot double-blind controlled study.
Mohammadi M; Shahram F; Shams H; Akhlaghi M; Ashofteh F; Davatchi F
Int J Rheum Dis; 2017 Sep; 20(9):1269-1276. PubMed ID: 28524639
[TBL] [Abstract][Full Text] [Related]
7. Determination of serum vascular endothelial growth factor (VEGF) and VEGF receptor levels with VEGF gene polymorphisms in patients with Behçet's uveitis.
Sertoglu E; Yücel Ç; Omma A; Hayran Y; Colak S; Sandıkçı SC; Durukan AH; Ozgurtas T
Adv Clin Exp Med; 2022 Mar; 31(3):231-240. PubMed ID: 34918882
[TBL] [Abstract][Full Text] [Related]
8. Current and future treatments for Behçet's uveitis: road to remission.
Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A
Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Behcet's Disease in the American Southwest.
Muruganandam M; Rolle NA; Sibbitt WL; Cook GB; Emil NS; Fangtham M; Reiter KJ; Bankhurst AD
Semin Arthritis Rheum; 2019 Oct; 49(2):296-302. PubMed ID: 30952423
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.
Gül A; Tugal-Tutkun I; Dinarello CA; Reznikov L; Esen BA; Mirza A; Scannon P; Solinger A
Ann Rheum Dis; 2012 Apr; 71(4):563-6. PubMed ID: 22084392
[TBL] [Abstract][Full Text] [Related]
11. A composite index for determining the impact of oral ulcer activity in Behcet's disease and recurrent aphthous stomatitis.
Mumcu G; Sur H; Inanc N; Karacayli U; Cimilli H; Sisman N; Ergun T; Direskeneli H
J Oral Pathol Med; 2009 Nov; 38(10):785-91. PubMed ID: 19614861
[TBL] [Abstract][Full Text] [Related]
12. Genital ulcer severity score and genital health quality of life in Behçet's disease.
Senusi A; Seoudi N; Bergmeier LA; Fortune F
Orphanet J Rare Dis; 2015 Sep; 10():117. PubMed ID: 26394620
[TBL] [Abstract][Full Text] [Related]
13. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH
Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798
[TBL] [Abstract][Full Text] [Related]
14. Interventions for the management of oral ulcers in Behçet's disease.
Taylor J; Glenny AM; Walsh T; Brocklehurst P; Riley P; Gorodkin R; Pemberton MN
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD011018. PubMed ID: 25254615
[TBL] [Abstract][Full Text] [Related]
15. Relationship between periodontal parameters and Behçet's disease and evaluation of different treatments for oral recurrent aphthous stomatitis.
Arabaci T; Kara C; Ciçek Y
J Periodontal Res; 2009 Dec; 44(6):718-25. PubMed ID: 19076988
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between serum IL-9 levels and Behçet's disease.
Nouri-Vaskeh M; Malek Mahdavi A; Khabbazi A; Jadideslam G
Immunol Lett; 2019 Jul; 211():23-27. PubMed ID: 31095970
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study.
Hirahara L; Kirino Y; Soejima Y; Takeno M; Takase-Minegishi K; Yoshimi R; Takeuchi M; Mizuki N; Nakajima H
Mod Rheumatol; 2021 Jul; 31(4):856-861. PubMed ID: 32996801
[TBL] [Abstract][Full Text] [Related]
18. Levels of soluble E-selectin in patients with active Behcet's disease.
Sari RA; Kiziltunç A; Taysi S; Akdemir S; Gündoğdu M
Clin Rheumatol; 2005 Feb; 24(1):55-9. PubMed ID: 15338451
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-17 mRNA expression and serum levels in Behçet's disease.
Jadideslam G; Kahroba H; Ansarin K; Sakhinia E; Abhar A; Alipour S; Farhadi J; Seydi Shirvani S; Nouri-Vaskeh M; Mousavi S; Khabbazi A
Cytokine; 2020 Mar; 127():154994. PubMed ID: 31951967
[TBL] [Abstract][Full Text] [Related]
20. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
